TargetMol

ALK inhibitor 1

Product Code:
 
TAR-T10285
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T10285-1mg1mg£135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10285-2mg2mg£165.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10285-5mg5mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10285-1mL1 mL * 10 mM (in DMSO)£266.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10285-10mg10mg£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10285-25mg25mg£550.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10285-50mg50mg£755.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10285-100mg100mg£1,010.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
ALK inhibitor 1 is a selective ALK kinase inhibitor.
CAS:
761436-81-1
Formula:
C23H28BrN7O3S
Molecular Weight:
562.49
Pathway:
Tyrosine Kinase/Adaptors; Angiogenesis; Cytoskeletal Signaling
Purity:
0.9855
SMILES:
CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCN(C)CC2)ncc1Br
Target:
FAK; IGF-1R; ALK

References

1. A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK).